Cefprozil Dispersible Tablets

This product is a second-generation cephalosporin drug with a broad-spectrum antibacterial effect. The bactericidal mechanism of this drug is to hinder the synthesis of bacterial cell walls. In vitro tests have shown that cefoperazone has a significant effect on Gram-positive aerobic bacteria such as Staphylococcus aureus (including (-lactamase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes, and has an inhibitory effect on Enterococcus tenacious, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus Warnei, Streptococcus agalactiae, Streptococcus C, D, F, G groups, and viridans streptococci. It is ineffective against methicillin-resistant Staphylococci and Enterococcus faecalis, and has no effect on Gram-negative aerobic bacteria such as Haemophilus influenzae (including (-lactamase-producing strains), Moraxella catarrhalis (including (-lactamase-producing strains), and It is highly sensitive to Citrobacter Diversus, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae (including (-lactamase-producing strains), Proteus mirabilis, Salmonella, Shigella and Vibrio, and has no antibacterial effect on most strains of Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia and Pseudomonas. Cefprozil has a certain inhibitory effect on melanin Bacillus, Clostridium difficile, Clostridium perfringens, Fusobacterium, Streptococcus and Propionibacterium acnes among anaerobic bacteria, and has no antibacterial effect on most strains of Bacillus fragilis.

The main component is cefprozil. Chemical name: (6R, 7R)-7-[(R)-2-amino-2-(p-hydroxy-phenyl)acetylamino]-8-oxo-3-propylene-5-thia-1-azabicyclo-(4,2,0)oct-2-ene-2-carboxylic acid monohydrate.

This product is off-white or light yellow tablets.

It is used for the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infection. 2. Lower respiratory tract infection. 3. Uncomplicated skin and skin soft tissue infections caused by Staphylococcus aureus (including penicillin mold strains) and Streptococcus pyogenes.

Oral. For adults (13 years and above) with upper respiratory tract infection, 0.5g (2 tablets) each time, once a day; for lower respiratory tract infection, 0.5g (2 tablets) each time, twice a day; for skin or skin soft tissue infection, 0.5g (2 tablets) per day, divided into 1 or 2 times; for severe cases, 0.5g (2 tablets) each time, twice a day. For upper respiratory tract infection in children aged 2 to 12 years, 7.5mg/kg body weight each time, twice a day; for skin or skin soft tissue infection, 20mg/kg body weight each time, once a day. For otitis media in infants from 6 months to 12 years old, 15mg/kg body weight each time, twice a day; for acute sinusitis, generally 7.5mg/kg body weight each time, twice a day; for severe cases, 15mg/kg body weight each time, twice a day. The course of treatment is generally 7 to 14 days, but the course of treatment for acute tonsillitis and pharyngitis caused by β-hemolytic streptococci is at least 10 days.

1. The adverse reactions of ceftriaxone are similar to those of other oral cephalosporins, mainly gastrointestinal reactions, including diarrhea, nausea, vomiting and abdominal pain. Allergic reactions may also occur, most commonly rash and urticaria. Allergic reactions are more common in children than in adults, and often occur within a few days after the start of treatment and disappear within a few days after stopping the drug. Other adverse reactions are rare, including: Hepatobiliary system: AST (aspartate aminotransferase) and ALT (alanine aminotransferase). Occasionally, alkaline phosphatase and bilirubin are increased. Cholestatic jaundice is rare. Central nervous system: dizziness, hyperactivity, headache, mental tension, insomnia, and occasionally drowsiness. All these reactions are reversible. Blood system: leukopenia, eosinophilia. Kidneys: Increased serum urea nitrogen and serum creatinine. Others: Diaper dermatitis-like skin

Contraindicated in patients allergic to cephalosporins.

Precautions for children: For upper respiratory tract infection in children aged 2 to 12 years, take 7.5 mg/kg of body weight once, twice a day; for skin or skin soft tissue infection, take 20 mg/kg of body weight once, once a day. For otitis media in infants from 6 months to 12 years old, take 15 mg/kg of body weight once, twice a day; for acute sinusitis, take 7.5 mg/kg of body weight once, twice a day; for severe cases, take 15 mg/kg of body weight once, twice a day. The course of treatment is generally 7 to 14 days, but the course of treatment for acute tonsillitis and pharyngitis caused by hemolytic streptococci is at least 10 days. There is no data on the safety and efficacy of cefprozil in children under 6 months of age. However, there have been reports of other cephalosporins accumulating in newborns (due to the extended half-life of drugs in children of this age group). Precautions during pregnancy and lactation: When lactating women take 1 gram of cefprozil orally at a time, a small amount of the drug (0.3% of the dose taken) can be measured in breast milk. The average concentration over 24 hours is 0.25 to 3.3 mg/l. Since the effect of cefprozil on infants is not yet clear, lactating women should be cautious when taking this product. Precautions for the elderly: The average AUC of the elderly (65 years old) is about 35% to 60% higher than that of young adults, and the AUC of women is 15% to 20% higher than that of men. However, the pharmacokinetics of cefprozil do not differ between age and gender enough to justify the need for dose adjustment.

There have been reports of nephrotoxicity caused by the combination of aminoglycosides and cephalosporins. The AUC of cefprozil can be doubled when used with probenecid. Drug/Laboratory Test Interactions Cephalosporin antibiotics can cause false positive reactions in urine glucose reduction tests [Benedict or Feling's reagents or copper sulfate tablets (Clinitest tablets), but urine glucose enzymatic tests, such as Tes-Tape (urine glucose test paper), do not produce false positives. This type of drug can cause false negative blood glucose ferrocyanide reactions. Cefprozil in the blood does not interfere with the determination of creatinine in the blood or urine by the alkaline picrate method.

Light-proof and sealed.

Calculated as C18H19N3O5S 0.25g

12 months.

Shanghai Meiyou Pharmaceutical Co., Ltd.

• Founded in:

  1998-02-26

• Address:

  No. 1388, Wusi Road, Fengxian District, Shanghai

• Tax NO.:

  91310120134051612H

• Registered Funds:

  64.8 million yuan

• Email:

  Log in to view